Outlook Therapeutics Resubmits FDA Application for Wet AMD Treatment

Event summary

  • Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ to the FDA for treating neovascular age-related macular degeneration (nAMD).
  • The FDA concluded that substantial evidence of effectiveness has been established, eliminating the need for additional trials.
  • The resubmission is classified as a Class 1 review with a PDUFA decision expected within 60 days of FDA’s receipt.
  • If approved, ONS-5010/LYTENAVA™ will be the first FDA-approved ophthalmic formulation of bevacizumab.

The big picture

Outlook Therapeutics' resubmission of the BLA for ONS-5010/LYTENAVA™ marks a critical step in bringing the first FDA-approved ophthalmic formulation of bevacizumab to market. The FDA's conclusion that substantial evidence of effectiveness has been established removes a significant regulatory hurdle. The company's ability to navigate the regulatory process efficiently will be key to its success in a competitive ophthalmology market.

What we're watching

Regulatory Approval
Whether the FDA will approve ONS-5010/LYTENAVA™ within the 60-day PDUFA review period.
Market Impact
How the approval of ONS-5010/LYTENAVA™ will affect the competitive landscape for wet AMD treatments.
Commercialization Strategy
The pace at which Outlook Therapeutics can commercialize the product in the U.S. following approval.